Literature DB >> 606798

Trials of influenza A/New Jersey/76 virus vaccine in normal children: an overview of age-related antigenicity and reactogenicity.

P F Wright, J Thompson, W K Vaughn, D S Folland, S H Sell, D T Karzon.   

Abstract

The total multicenter data from trials with inactivated monovalent influenza A/New Jersey/76 virus vaccine in 2,326 normal children were collected and summarized at Vanderbilt University (Nashville, Tenn.). These combined data provided the best measure of the relative antigenicity and reactogenicity of each manufacturer's vaccine. Children younger than 10 years of age were shown to have vaccine-associated reactions to doses of whole-virus vaccine containing as little as 50 chick cell-agglutinating units. Split-virus vaccines were well tolerated in doses eight times as high. No vaccine was satisfactorily antigenic in a single dose. A two-dose regimen of split-virus vaccine was antigenic, and this regimen was not associated with acute reactions.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 606798     DOI: 10.1093/infdis/136.supplement_3.s731

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  33 in total

1.  Developing vaccines against pandemic influenza.

Authors:  J M Wood
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2001-12-29       Impact factor: 6.237

2.  Protective immunity against H5N1 influenza virus by a single dose vaccination with virus-like particles.

Authors:  Jae-Min Song; Jaber Hossain; Dae-Goon Yoo; Aleksandr S Lipatov; C Todd Davis; Fu-Shi Quan; Li-Mei Chen; Robert J Hogan; Ruben O Donis; Richard W Compans; Sang-Moo Kang
Journal:  Virology       Date:  2010-06-26       Impact factor: 3.616

3.  Fever following immunization with influenza A (H1N1) vaccine in children: a survey-based study in the Netherlands.

Authors:  Nancy Broos; Eugène P van Puijenbroek; Kees van Grootheest
Journal:  Drug Saf       Date:  2010-12-01       Impact factor: 5.606

Review 4.  The threat of avian influenza A (H5N1). Part IV: Development of vaccines.

Authors:  Jindrich Cinatl; Martin Michaelis; Hans W Doerr
Journal:  Med Microbiol Immunol       Date:  2007-06-01       Impact factor: 3.402

Review 5.  H5N1 vaccines in humans.

Authors:  Mariana Baz; Catherine J Luke; Xing Cheng; Hong Jin; Kanta Subbarao
Journal:  Virus Res       Date:  2013-05-28       Impact factor: 3.303

6.  Technical guidelines for the application of seasonal influenza vaccine in China (2014-2015).

Authors:  Luzhao Feng; Peng Yang; Tao Zhang; Juan Yang; Chuanxi Fu; Ying Qin; Yi Zhang; Chunna Ma; Zhaoqiu Liu; Quanyi Wang; Genming Zhao; Hongjie Yu
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

7.  Safety and immunogenicity of inactivated, Vero cell culture-derived whole virus influenza A/H5N1 vaccine given alone or with aluminum hydroxide adjuvant in healthy adults.

Authors:  Wendy A Keitel; Cornelia L Dekker; ChrisAnna Mink; James D Campbell; Kathryn M Edwards; Shital M Patel; Dora Y Ho; Helen K Talbot; Kuo Guo; Diana L Noah; Heather Hill
Journal:  Vaccine       Date:  2009-03-25       Impact factor: 3.641

Review 8.  Influenza vaccines.

Authors:  A H Ellebedy; R J Webby
Journal:  Vaccine       Date:  2009-11-05       Impact factor: 3.641

9.  Preclinical evaluation of a replication-deficient intranasal DeltaNS1 H5N1 influenza vaccine.

Authors:  Julia Romanova; Brigitte M Krenn; Markus Wolschek; Boris Ferko; Ekaterina Romanovskaja-Romanko; Alexander Morokutti; Anna-Polina Shurygina; Sabine Nakowitsch; Tanja Ruthsatz; Bettina Kiefmann; Ulrich König; Michael Bergmann; Monika Sachet; Shobana Balasingam; Alexander Mann; John Oxford; Martin Slais; Oleg Kiselev; Thomas Muster; Andrej Egorov
Journal:  PLoS One       Date:  2009-06-19       Impact factor: 3.240

Review 10.  Prevention and control of influenza in persons with chronic obstructive pulmonary disease.

Authors:  Pedro Plans-Rubió
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2007
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.